XRTX Fundamental Analysis - XORTX THERAPEUTICS INC

Fundamental Rating

XRTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. While XRTX seems to be doing ok healthwise, there are quite some concerns on its profitability. XRTX is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XRTX has reported negative net income.

In the past year XRTX has reported a negative cash flow from operations.

In the past 5 years XRTX always reported negative net income.

XRTX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

XRTX has a worse Return On Assets (-68.60%) than 66.84% of its industry peers.

XRTX has a Return On Equity (-92.63%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-68.6%
ROE	-92.63%
ROIC	N/A

ROA(3y)-60.92%

ROA(5y)-49.27%

ROE(3y)-85.37%

ROE(5y)-73.65%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XRTX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for XRTX has been increased compared to 1 year ago.

XRTX has less shares outstanding than it did 5 years ago.

Compared to 1 year ago, XRTX has a worse debt to assets ratio.

2.2 Solvency

XRTX has an Altman-Z score of -8.57. This is a bad value and indicates that XRTX is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -8.57, XRTX is not doing good in the industry: 65.31% of the companies in the same industry are doing better.

XRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-8.57

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 1.78 indicates that XRTX should not have too much problems paying its short term obligations.

With a Current ratio value of 1.78, XRTX is not doing good in the industry: 64.29% of the companies in the same industry are doing better.

XRTX has a Quick Ratio of 1.78. This is a normal value and indicates that XRTX is financially healthy and should not expect problems in meeting its short term obligations.

XRTX has a Quick ratio (1.78) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	1.78
Quick Ratio	1.78

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

XRTX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.07%.

EPS 1Y (TTM)-8.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-423.38%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-11.64%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XRTX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XRTX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XRTX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

XORTX THERAPEUTICS INC

NASDAQ:XRTX (10/10/2025, 9:04:05 PM)

After market: 0.87 -0.01 (-1.24%)

0.8809

-0.03 (-2.8%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-12 2025-08-12

Earnings (Next)11-12 2025-11-12

Inst Owners1.23%

Inst Owner Change0%

Ins Owners2.63%

Ins Owner ChangeN/A

Market Cap4.59M

Analysts80

Price TargetN/A

Short Float %0.39%

Short Ratio0.31

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.26
P/tB	2.5
EV/EBITDA	N/A

EPS(TTM)-0.54

EYN/A

EPS(NY)-1.55

Fwd EYN/A

FCF(TTM)-0.6

FCFYN/A

OCF(TTM)-0.59

OCFYN/A

SpS0

BVpS0.39

TBVpS0.35

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-68.6%
ROE	-92.63%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-60.92%

ROA(5y)-49.27%

ROE(3y)-85.37%

ROE(5y)-73.65%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	49.57%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.78
Quick Ratio	1.78
Altman-Z	-8.57

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)48.3%

Cap/Depr(5y)87.61%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-8.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-423.38%

EPS Next Y-11.64%

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y31.68%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-29.82%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y58.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y58.89%

OCF growth 3YN/A

OCF growth 5YN/A

XORTX THERAPEUTICS INC (XRTX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens